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and salmeterol on in vitro T-cell activation
and apoptosis in asthma
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Stefania La Grutta, MD,a Maria Ferraro, PhD,a Liboria Siena, PhD,a
Giovanni Bonsignore, MD,a Mark Gjomarkaj, MD,a Jean Bousquet, MD,b and
Antonio M. Vignola MD, PhDa Palermo, Italy, and Montpellier, FranceBackground: In asthma T cells are characterized by an
increased activation state and by reduced apoptosis.
Objective: Because the clinical efficacy of inhaled
corticosteroids combined with long-acting b2-agonists has been
widely demonstrated in asthma, we studied, in vitro, the effect
of fluticasone propionate (FP) and salmeterol alone and in
combination on the activation and apoptosis of peripheral
blood T cells (PBTs), on the expression of phosphorylated
nuclear factor kB inhibitor (IkBa), and on the nuclear
translocation of glucocorticoid receptor (GR) in PBTs from
asthmatic subjects.
Methods: Apoptosis was evaluated on the basis of annexin V
binding, whereas the expression of caspases 8 and 3 and
phosphorylated IkBa, as well as the nuclear translocation of
the GR, were evaluated by means of Western blot analysis.
Results: FP alone increases and salmeterol alone does not affect
T-cell apoptosis. The combination of FP and salmeterol
significantly increases PBT apoptosis in comparison with FP
alone. FP at the lower concentration, when combined with
salmeterol, is equivalent to FP at the higher concentration in
inducing PBT apoptosis. The synergy in the induction of cell
apoptosis is associated with more efficient activation of caspases
8 and 3. FP plus salmeterol is also able to synergistically reduce
the expression of phosphorylated IkBa, thus limiting nuclear
factor kB activation. The synergy was related to an increased
nuclear translocation of the GR.
Conclusion: This study shows that the combination of FP and
salmeterol is able to control PBT activation in asthmatic
patients more efficiently than FP alone and with a lower
concentration of steroids. (J Allergy Clin Immunol
2004;114:1216-23.)
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doi:10.1016/j.jaci.2004.07.0521216T cells play a central role in the airway inflammation
seen in asthma.1,2 Their accumulation at the site of
inflammation is related to an increased recruitment from
the peripheral blood and prolonged survival.3 Cell apo-
ptosis is one of the mechanisms involved in the control of
T-cell homeostasis,4 causing the deletion of autoreactive T
cells.5 Most T cells in the airways of untreated asthmatic
patients are not apoptotic.6 Moreover, in patients with
asthma, peripheral blood T cells (PBTs) are characterized
by an increased activation state and by reduced apoptosis.7
A persistent activation of the transcription nuclear
factor kB (NF-kB)/inhibitor of NF-kB (IkB) systemmight
represent one of the mechanisms by which T-cell apopto-
sis is reduced.8 This might be associated with the
activation of the IkBa kinases that phosphorylate IkBa,
the most predominant NF-kB inhibitor. The phosphory-
lation of IkBa generates, in turn, the detachment of IkBa
from NF-kB, as well as IkBa degradation itself. As
a result of these phenomena, NF-kB translocates into the
nucleus and activates the transcription of target genes.9
The efficacy of the combination of inhaled cortico-
steroids (ICSs) with long-acting b2-agonists (LABAs) in
the therapy of asthma has been widely demonstrated.10 A
possible explanation for this efficacy is represented by
a synergistic interaction between ICSs and LABAs at
a molecular level. In a model of fibroblasts and vascular
smooth muscle cells, LABAs upregulate the activity of
ICSs by promoting the translocation of glucocorticoid
receptor (GR) into the nuclei of these cells.11
We have previously demonstrated that fluticasone
propionate (FP) is able to induce peripheral blood T-cell
Abbreviations used
FP: Fluticasone propionate
GR: Glucocorticoid receptor
ICS: Inhaled corticosteroid
IkB: Inhibitor of nuclear factor kB
LABA: Long-acting b2 agonist
NF-kB: Nuclear factor kB
PBT: Peripheral blood T cell
PDTC: Pyrrolidinedithiocarbamic acid
pIkBa: Phosphorylated inhibitor of NF-kB
PKC: Protein kinase C
PMA: Phorbol myristate acetate
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Pace et al 1217FIG 1. FP and salmeterol (SMR) in combination synergistically induce apoptosis of resting peripheral T cells
(n = 10). PBTs were isolated and cultured with and without FP and salmeterol alone or in combination for
24 (A) and 72 (B) hours. T-cell apoptosis was evaluated on the basis of annexin V binding and expressed as
the percentage of annexin V–positive cells. *P < .05 compared with baseline. **P < .05 compared with FP
alone.B
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the NF-kB activation in PBTs.12 Despite this, the effects
of the combination of ICSs and LABAs on T cells has not
yet been firmly established.
The aims of this studywere to assess (1) whether FP and
salmeterol exert a synergistic effect on T-cell apoptosis;
(2) whether FP and salmeterol exert a combined down-
regulatory effect on NF-kB activation of T cells through
reduced degradation of its endogenous inhibitor, IkBa;
and (3) whether these synergistic effects are related to
increased translocation of the GR from the cytosol to the
nuclei of T cells.METHODS
Subjects
We selected 15 patients with mild intermittent asthma (age,
9-13 years), according to the criteria of the American Thoracic
Society. The diagnosis of asthma and the assessment of its
severity were performed at study entry according to Global
Initiative for Asthma guidelines.13 None of the patients re-
ceived any corticosteroid treatment during the previous 2
weeks.
The study fulfilled the criteria of the ethics committee of our
hospital, and all subjects, parents, or both provided informed
consent.
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PBTs were obtained from 20 mL of heparinized blood from
asthmatic patients, as previously described.14 The recovered PBT
fraction was greater than 97% CD31, as assessed by means of
cytofluorimetric analysis.
PBT cultures
PBTs were incubated in the absence or presence of FP (1028,
1029, and 10210 M; GlaxoSmithKline, London, United Kingdom),
salmeterol (1027 M; GlaxoSmithKline),15,16 or in combination with
propranolol (10 mM, 30 minutes; Sigma Chemical Co, St Louis, Mo)
before incubation with salmeterol.17 The concentration range of FP
and the incubation times (24 and 72 hours) were previously shown to
be optimal to induce cell apoptosis.7 Cell viability was assessed by
means of trypan blue dye exclusion. In some experiments PBTs were
cultured with anti-CD3 mAb (100 ng/mL; Dakopatts, Glostrup,
Denmark) or with phorbol myristate acetate (PMA; 2-20 ng/mL;
Sigma) for 24 hours, as previously reported.18 In other experiments
PBTs were pretreated with Ac-IETD-CHO, an inhibitor of caspase 8
(1 hour, 60 mM; Pharmingen, San Jose, Calif) or with Ac-DEVD-
CHO, an inhibitor of caspase 3 (1 hour, 60mM;Pharmingen) and then
cultured with FP, salmeterol, or both for 24 hours (37C, 5% CO2).
PBTs were cultured with pyrrolidinedithiocarbamic acid (PDTC; 500
mM, 24 hours; Sigma), an inhibitor of NF-kB, to evaluate the role of
NF-kB.12 To evaluate pIkBa and GR nuclear translocation, PBTs
were cultured (37C, 5% CO2) with FP, salmeterol, or both for 30
minutes.
PBT phenotype analysis and apoptosis
detection
T-cell apoptosis was determined, as previously described,7 by
evaluating annexin V expression. Apoptotic cells were identified by
means of double or triple staining with an Annexin V–FITC kit
(Bender MedSystem, Vienna, Austria) and anti-human Peridinin
Chlorophyll Protein–CD3 (Becton Dickinson, San Jose, Calif) and
anti-human phycoerythrin (RPE)–conjugated CD8, (Dakopatts
Glostrup) or anti-human RPE-conjugated CD4 clone MT310
(Dakopatts). Cell apoptosis and the phenotype of PBTs were
determined by using a FACS Escalibur Plus flow cytometer
(Becton Dickinson). Phycoerythrin-conjugated (X-928, Dakopatts)
and FITC-conjugated mouse anti-human IgG1 (X-927, Dakopatts)
were used as negative controls.
Western blot analysis for caspases 3 and 8,
phosphorylated inhibitor of nuclear factor
kB (pIkBa) detection, and GR nuclear
translocation
Western blot analysis for caspase 3 and 8 expression, for pIkBa
detection, and for GR translocation was performed as previously
TABLE I. Phenotype of annexin V–positive cells (24 hours
of incubation, n = 5, mean 6 SD)
CD3 CD4 CD8
Baseline 9.8 6 1.6 5.2 6 0.7 4.5 6 0.8
1029 M FP 21.4 6 5.6 12.2 6 5 9 6 2.5
1029 M FP 1
1027 M salmeterol
24 6 5 13.5 6 4.7 10 6 2
P < .05, FP plus salmeterol versus FP alone and versus baseline.described.12,19 The cytoplasmic and nuclear protein fractions were
separated by using a commercial kit (Pierce, Rockford, Ill) to study
GR nuclear translocation. Fifty micrograms of total protein was
subjected to SDS-PAGE on 4% to 12% gradient gels (Novex, San
Diego, Calif), blotted onto nitrocellulose membranes, blocked with
PBS containing 3% BSA and 0.1% Tween 20, and then probed with
a polyclonal antibody directed against human procaspases 3 and 8
(Pharmingen and Becton Dickinson), with a polyclonal antibody
directed against human GRa (Santa Cruz Biotechnology, Santa Cruz,
Calif) or with a polyclonal antibody recognizing pIkBa (Santa Cruz
Biotechnology). Detection was performed with an enhanced chem-
iluminescence system (NEN, Boston, Mass), followed by autoradi-
ography. Negative controls were performed in the absence of primary
antibody or including an isotype control antibody. b-actin (Sigma)
was used as a housekeeping protein. Gel images were taken with an
EPSON GT-6000 scanner and then imported to a National Institutes
of Health Image analysis 1.61 program to determine band density.
Data are expressed as arbitrary densitometric units corrected against
the density of b-actin bands.
Statistical analysis
Data are expressed as mean counts6 SD. Statistical analysis was
performed with repeated-measures ANOVA with nonparametric
Kruskal-Wallis analysis and ANOVA with the Bonferroni Dunn
correction. A P value of less than .05 was accepted as statistically
significant.
RESULTS
FP and salmeterol in combination increase
apoptosis in resting PBTs
FP significantly increased PBT apoptosis in a dose-
dependent manner when compared with baseline values,
whereas salmeterol alone did not affect spontaneous PBT
apoptosis at either tested time point. Interestingly, the
combined presence of FP at all the tested concentrations
and salmeterol was able to significantly increase PBT
apoptosis at both time points. Moreover, FP at the
concentration of 1029 M when combined with salmeterol
was not statistically different from FP at the concentration
of 1028 M in inducing PBT apoptosis (Fig 1). Propranolol
blocked FP- and salmeterol-induced T-cell apoptosis (data
not shown). Both CD41 and CD81 cells composed the
apoptotic CD3 population (Table I).
FP and salmeterol in combination
synergistically increase anti-CD3–activated
PBT apoptosis
The addition of 1029 M FP to PBTs stimulated with
anti-CD3 mAb significantly (P < .05) increased their
apoptosis in comparison with the presence of anti-CD3
mAb alone. As expected, the addition of salmeterol alone
did not exert any additional proapoptotic effects in anti-
CD3–stimulated cultures. Nonetheless, the combination
of FP and salmeterol was able to significantly increase
anti-CD3–induced apoptosis compared with levels seen in
the presence of FP alone (Fig 2).
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Pace et al 1219FIG 2. FP and salmeterol (SMR) in combination synergistically induce apoptosis of CD3-activated peripheral
T cells (n = 7). *P < .05 compared with FP alone. PBTs were stimulated with anti-CD3 in the presence and
absence of FP (1029 M) and salmeterol (1027 M) alone or in combination for 24 hours. Data are expressed as
the percentage of control values (anti-CD3–stimulated cells). *P < .05 compared with FP alone.B
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synergistically increase caspase activation
The presence of FP alone significantly decreased the
levels of procaspase 8, whereas, as expected, the presence
of salmeterol alone did not affect this level. Moreover, the
presence of FP and salmeterol in combination further
reduced the levels of procaspase 8 (Fig 3, A and C). With
regard to procaspase 3, when PBTs were cultured in the
presence of FP alone, a significant decrease of procaspase
3 levels occurred. Salmeterol alone did not affect the level
of procaspase 3. The presence of FP and salmeterol in
combination was able to further decrease the level of
procaspase 3 (Fig 3, B and C).
FP and FP-salmeterol proapoptotic activity
is dependent on caspase activation
Weperformed experiments with PMA as an activator of
protein kinase C (PKC) and as an agent capable of
blocking caspase 8 activation.20 The addition of FP alone
or in combination with salmeterol to PMA-stimulated
PBTs was not able to induce apoptosis at either concen-
tration of PMA (Fig 4, A). The presence of PMA alone
induced T-cell apoptosis (data not shown). To gain insight
into the impairment of FP and FP-salmeterol proapoptotic
activity in the presence of PMA, we evaluated the levels of
procaspases 8 and 3 in FP, salmeterol, and FP-salmeterol
PMA-stimulated cultures. Interestingly, procaspase 8 and
3 activation in PMA-stimulated PBTs cultured with FP
and with the FP-salmeterol combination was blocked
(Fig 4, B). In addition, the inhibition of caspase 8 and
3 activation by Ac-IETD-CHO and Ac-DEVD-CHOblocked both the proapoptotic activity of FP and that of
the FP-salmeterol combination (Fig 5).
FP and salmeterol in combination decrease
IkBa phosphorylation
The inhibition of NF-kB by PDTC was able to
significantly increase PBT apoptosis (baseline, 19 6 4;
PDTC, 336 9; Wilcoxon P < .05). In addition, FP at both
tested concentrations was able to reduce IkBa phosphor-
ylation more efficiently than salmeterol. Moreover, the
combination of FP and salmeterol at both tested FP
concentrations was able to further reduce IkBa phosphor-
ylation when compared with the effects exerted by FP or
salmeterol alone (Fig 6).
FP and salmeterol in combination increase
the translocation of the GR from the cytosol
to the nucleus of PBTs
Finally, we tested whether the synergistic activities
exerted by FP and salmeterol in combination might be
related to an increased nuclear translocation of the GR in
PBTs. FP at the lesser and greater tested concentrations
was able to dramatically decrease and completely abrogate
the presence of GR in the cytosol, respectively. Moreover,
the addition of salmeterol to FP at the lesser concentration
was also able to abrogate the presence of the GR in the
cytosol. Consequently, the decrease or the complete
abrogation of the presence of the GR in the cytosol was
paralleled by an increased presence of the GR in the
nucleus (Fig 7), demonstrating that the addition of
salmeterol to FP increases glucocorticoid activities
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(n = 7). A and B, Densitometric analysis of procaspases 8 and 3, respectively. *P < .05 compared with baseline.
**P < .05 compared with FP alone. C, Western blot analysis of procaspases 8 and 3 and b-actin expression by
PBTs. Lane 1, Baseline; lane 2, 1029 M FP; lane 3, 1027 M salmeterol; lane 4, 1029 M FP plus 1027 M salmeterol.through a more effective translocation of the GR into the
nucleus.
DISCUSSION
A main goal of asthma therapy is to achieve optimal
control of airway inflammation. ICSs are the mainstay of
asthmamanagement and are extremely effective inhibitors
of T-cell activation7 and TH2 cytokine production.
21
Previous reports demonstrated the clinical utility of
combined use of glucocorticoids and LABAs in the
improvement of patient symptoms and airflow limita-
tion.10 This study shows, for the first time, a synergistic
proapoptotic effect of FP and salmeterol on resting and
activated T cells isolated from the peripheral blood of
asthmatic patients, the basis of which seems to be due to an
increased GR nuclear translocation and enhanced in-
hibition of IkBa phosphorylation. These effects are
crucial because they provide an effective control of the
T cell–related inflammation, a key component of asthma
pathogenesis. The persistence of T-cell activation in
asthma might be related to reduced T-cell apoptosis,3generating, in turn, prolonged release of inflammatory
soluble factors amplifying both asthma-associated in-
flammation and airway damage.2
We have previously demonstrated that in asthmatic
patients FP is able to increase cell apoptosis of both resting
and IL-2–stimulated PBTs.7 We now show that this FP-
mediated effect on resting PBTs is increased by the
addition of salmeterol, suggesting that the synergistic
effects on asthma symptoms might be related, at least in
part, to their ability to reduce T- cell survival. Both CD41
and CD81 PBTs are sensitive to both FP and the FP-
salmeterol combination, suggesting that this proapoptotic
effect is not restricted to a subtype of CD31 cells. Despite
this, a great proportion of PBTs remains resistant to FP-
and FP-salmeterol–induced apoptosis and is consistent
with our previous observations.7 This is likely related to
the expression of survival markers (ie, bcl-2) exerting
a protective effect against apoptosis. On a speculative
level, the relatively limited proapoptotic effect of FP
and salmeterol on CD31 cells might prevent a mas-
sive depletion of these cells during the pharmacologic
treatment, avoiding potential impairment of host de-
fenses.
J ALLERGY CLIN IMMUNOL
VOLUME 114, NUMBER 5
Pace et al 1221FIG 4. PMA blocks the apoptosis and the caspase 8 and 3 activation of PBTs (n = 5). PBTs were stimulated with
PMA and FP (1029 M) and salmeterol (SMR; 1027 M) alone or in combination for 24 hours. A, PBT apoptosis
expressed as the percentage of PMA-stimulated cells. P < .05 versus PMA alone. B, Western blot analysis of
procaspases 8 and 3 by PMA-stimulated PBTs. Lane 1, Baseline; lane 2, 1029 M FP; lane 3, 1027 M salmeterol;
lane 4, 1029 M FP plus 1027 M salmeterol. Table, Densitometry of procaspases 3 and 8.B
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at lower concentrations in combination with salmeterol is
similar to the levels seen with higher concentrations
of FP alone. This supports the notion that FP and
salmeterol combination therapy should permit the phy-
sician to use a lower concentration of steroid in the
therapy of asthma, thereby reducing potential side
effects. Additionally, the ability of propranolol to reverse
the increase of PBT apoptosis induced by FP-salmeterol
confirms that this phenomenon is mediated by b2
receptor activation.
To evaluate whether these effects were also exerted in
activated T cells, we stimulated PBTs from asthmatic
patients with an anti-CD3 mAb. It has been demonstrated
that the stimulation of the T-cell receptor/CD3 complex
leads to T-cell activation and to a reduced responsiveness
to dexamethasone in murine T-cell hybridomas.18 Ourfindings that FP is able to increase the anti-CD3–
stimulated T-cell apoptosis differently than the effects
exerted by dexamethasone on T-cell hybridomas confirms
that FP is a more effective steroid in exerting a proapop-
totic activity on CD3-stimulated T cells.22 Another
possible explanation of this different response might also
be related to the use of a different T-cell target. Similar to
the effects exerted on resting T cells, the addition of
salmeterol to FPwas able to significantly increase the anti-
CD3–stimulated PBT apoptosis in comparison with both
FP and salmeterol alone, suggesting that the proapoptotic
effects of combined treatment also occur on activated
PBTs.
Several studies report that sequential cleavage and ac-
tivation of caspases are important mechanisms in most
apoptosis models and that glucocorticoids are able to
induce apoptosis through the activation of caspases 8
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yFIG 5. Inhibitors of caspases 8 and 3 block the apoptosis of PBTs (n = 5). PBTs were incubated with an inhibitor
of caspase 8 (Ac-IETD-CHO) and with an inhibitor of caspase 3 (Ac-DEVD-CHO) and then cultured with FP (1029
M) and salmeterol (SMR; 1027 M) either alone or in combination for 24 hours. T-cell apoptosis was expressed
as the percentage of annexin V– positive cells. *P < .05 compared with 1029 M FP. **P < .05 compared with
1029 M FP plus 1027 M salmeterol.and 3. In particular, recent work demonstrated that the
activation of the caspase 8–caspase 3 pathway is involved
in the dexamethasone-induced apoptosis of thymocytes.23
Accordingly, we demonstrated, for the first time, that the
FIG 6. FP and salmeterol (SMR) in combination reduce synergis-
tically phosphorylated IkBa expression (n = 7). A, Densitometric
analysis of pIkBa. *P < .05 compared with the baseline. **P < .05
compared with FP. B, Western blot analysis of pIkBa and b-actin
expression by PBTs. Lane 1, Baseline; lane 2, 1028 M FP; lane 3,
1029 M FP; lane 4, 1027 M salmeterol; lane 5, 1028 M FP plus 1027 M
salmeterol; lane 6, 1029 M FP plus 1027 M salmeterol.presence of FP, as well as that of FP plus salmeterol, is
associated with the decreased levels of procaspases 8 and
3 because of their activation in PBTs.23
To evaluate whether the activation of caspases was
a crucial step in PBT apoptosis induced by FP and by FP
plus salmeterol, we stimulated PBTs with PMA, which
promotes PKC activation and inhibits caspase 8 cleavage
and activation.20 In this regard we also blocked caspase 8
and 3 activation with specific inhibitors in concomitant
cultures. Our findings that the proapoptotic effects of FP
and of FP plus salmeterol were inhibited by the presence
of PMA and by specific inhibitors of caspases 8 and 3
strongly support the hypothesis that activation of caspases
8 and 3 is a crucial step in the proapoptotic activity of FP.
Moreover, it is also conceivable that the reduced response
to FP in PMA-pretreated PBTs might be linked to PKC
activation, which in turn leads to increased GR turnover
and GR downregulation.24,25 Another route related to the
modulation of apoptosis by glucocorticoids is through
NF-kB, a transcription factor induced by proinflammatory
cytokines.26,27 A persistent activation of the NF-kB/IkB
system might represent one of the mechanisms by which
PBT apoptosis is reduced.8 Although there is some
controversy about the role of this transcription factor in
cell apoptosis, most data support an NF-kB antiapoptotic
action.28 In addition, it has been shown that cells that are
naturally resistant to TNF-induced apoptosis become
susceptible when transfected with an expression vector
for IkBa, which inactivates NF-kB.26 Consistent with
these findings, we observed that the presence of FP and,
to a greater extent, the combined presence of FP and
salmeterol reduced the expression of phosphorylated
IkBa, which, in turn, leads to an increased IkBa
concentration and inhibition of NF-kB activity.
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salmeterol combination on the nuclear translocation of
GR. Glucocorticoids act through interaction with a cyto-
plasmic GR that functions as a transcription factor in the
nucleus. Dexamethasone-induced apoptosis is mRNA and
protein synthesis dependent, requiring dexamethasone-
GR interaction and the consequent GR nuclear trans-
location.29 Consistent with this, we demonstrated that the
PBT apoptosis induced by FP is associated with nuclear
translocation of GR and that a further increase in trans-
location is observedwhen FP is combinedwith salmeterol.
These findings suggest that the synergistic effects on PBT
apoptosis and on the phosphorylation process of IkBa
might occur at the level of the nuclear translocation of the
GR. In contrast to Eickelberg et al,11 salmeterol alone did
not induce nuclear translocation of the GR. Importantly, it
must be noted, this apparent discrepancy might be due to
the lower b2 receptor expression in PBTs compared with
that seen in fibroblasts and vascular smooth muscle
cells.30
In conclusion, this study shows that the combination of
FP and salmeterol is able to control PBT activation in
asthmatic patients more efficiently than FP alone and
with a lower concentration of steroid by increasing apo-
ptosis and by inhibiting the NF-kB of PBT and that this
synergy is related to an increased nuclear translocation of
the GR.
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